Rapid response to behavioral/pharmacological obesity treatments for binge‐eating disorder predicts better clinical outcomes
Authors' conclusion
In a randomized clinical trial testing behavioral and pharmacological obesity treatments for BED with co-occurring obesity, rapid response was a robust prognostic indicator of binge-eating remission and significantly better behavioral, psychological, and metabolic outcomes. Non-rapid response to behavioral and pharmacological obesity treatments could signal a need to switch to alternative treatments.
Study context
- Population
- Participants with binge-eating disorder (BED) and obesity in an RCT of 16-week behavioral and/or pharmacological (naltrexone/bupropion) obesity interventionsrandomized 2 × 2 factorial
- Participants
- 136 participants
- Comparison
- Rapid response vs non-rapid response to behavioral and/or pharmacological (naltrexone/bupropion) obesity treatments
- Rapid responsen = 75
- Primary endpoint
- Rapid response (≥65% reduction in binge-eating episode frequency after 1 month) and its prognostic significance
- Follow-up
- 1 month of treatment
Methodological detailsbalanced 2 × 2 factorial, masked assessments
- Balanced 2 × 2 factorial
- Masked assessments
Primary result
As reported in the abstract
Rapid response · after 1 month of treatment
Rapid response observed
55%
n = 75/136
Further findings
Binge-eating remission and outcomes at posttreatment
- Rapid response associated with binge-eating remission
- Rapid response associated with greater reductions in binge-eating frequency, eating-disorder psychopathology, percent weight loss, and metabolic variables (total cholesterol, HbA1c) (mixed models)
- Rapid response effects on outcomes did not vary by treatment
Original publication
Rapid response to behavioral/pharmacological obesity treatments for binge‐eating disorder predicts better clinical outcomes. Obesity (Silver Spring). Published 23 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →